Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
page 21 is wrong also, how can you have data for HOT first half 2019? copy and paste error from NEO.
ADXS-HOT NSCLC • Clinical data from initial cohort (safety, immune response) 1H 2019
The fxcking letter so big, how could someone make that kind of mistake! is that a hint?
Who knows, maybe is not!
HOT partner with AMGEN !!!!!!New Presentation is up! page 14 HOT partnership with AMGEN!!!! is that true or type error?
https://www.advaxis.com/wp-content/uploads/2018/08/Corporate_Presentation_-_August_2018.pdf
How about this? I'm afraid he will say this again with Advaxis "After a comprehensive review of strategic alternatives that included financings, acquisitions, mergers, asset monetization and corporate partnerships, we determined that this proposed transaction with Genoptix is in the best interest of all Rosetta Genomics stakeholders, including our equity holders. Our current cash position is sufficient to fund operations only until the end of 2017, and given our current market capitalization, potential for pending delisting from the Nasdaq Capital Market and the difficult financing environment for microcap molecular diagnostics companies, we do not believe we could raise sufficient capital to continue as a going concern for an extended period of time," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
Watch ken's video on youtube
Any reason Aduro up almost 10% today?
Ken is waiting s3 to be effective, so he could issue news regarding dilution again. will be announced at cc.
Many major investor conferences is coming, don't see any new events on the website. Are we set for the fund? or the company is near collapse again? or the company is sold?
Rosetta Genomics Files for Chapter 7 Bankruptcy,
Jun 04, 2018 | staff reporter
NEW YORK (GenomeWeb) – Rosetta Genomics last week filed for Chapter 7 bankruptcy, just one day after disclosing that its planned merger with Genoptix was in trouble.
Late last year, Genoptix agreed to acquire Rosetta for $10 million in cash, but that deal failed to garner enough support from Rosetta shareholders. The companies later signed another merger agreement that valued Rosetta at $9 million and was ultimately approved by Rosetta's investors.
While the transaction was slated to close on May 27, Rosetta said on May 30 that Genoptix had "refused to provide assurances that it intends to complete the transaction" due to an undisclosed "material adverse effect" affecting Rosetta, as well as breaches of representations and warranties.
Rosetta disputed Genoptix's claims, and said that it would file for bankruptcy protection if the merger was not consummated. According to documents filed with the US Bankruptcy Court for the District of Delaware, Rosetta filed for Chapter 7 bankruptcy on May 31.
Under Chapter 7 bankruptcy, a company seeks to liquidate its assets. Among Rosetta's listed creditors are Agilent Technologies, Fisher Scientific, Integrated DNA Technologies, and Sigma Aldrich.
Rosetta had offices in Israel and New Jersey and developed and commercialized microRNA-based diagnostic tests for various cancers. During the past year, the company underwent a series of strategic moves as its business struggled. In September, it announced layoffs as part of a plan to trim $1.7 million in expenses. It also agreed to sell its PersonalizeDx unit for $2.9 million.
The company also found itself in trouble with the Nasdaq for failing to meet certain listing requirements.
Because Cantor no longer working for Advaxis, that's why they canceled!
will Ken go to repeat these words again with advaxis? Why BOD hired him?
"After a comprehensive review of strategic alternatives that included financings, acquisitions, mergers, asset monetization and corporate partnerships, we determined that this proposed transaction with Genoptix is in the best interest of all Rosetta Genomics stakeholders, including our equity holders. Our current cash position is sufficient to fund operations only until the end of 2017, and given our current market capitalization, potential for pending delisting from the Nasdaq Capital Market and the difficult financing environment for microcap molecular diagnostics companies, we do not believe we could raise sufficient capital to continue as a going concern for an extended period of time," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
This is going to happen with Advaxis with Ken manage
Rosetta Genomics, Genoptix Sign New Merger Agreement
Feb 28, 2018 | staff reporter
NEW YORK (GenomeWeb) – Rosetta Genomics has agreed to a $9 million buyout by Genoptix, marking the companies' second attempt at a merger.
In December, Genoptix signed an agreement to acquire Rosetta for $10 million in cash. The deal came at a key time for Rosetta, which has undergone a series of organizational changes in recent months — including layoffs — and expects to run out of cash before the end of the year.
Last week, however, Rosetta disclosed that it had failed to secure the necessary shareholder approval for the merger and that it would be obligated to reimburse Genoptix $750,000.
The companies have now agreed on another merger deal, under which Genoptix would acquire Rosetta's PersonalizeDx business for $1 million in cash and then buy the remainder of Rosetta for $8 million in cash. Rosetta had previously said that it would sell PersonalizeDx to healthcare business group Pragmin Prognosis for $2.9 million in cash.
The companies said that — after deducting expected payments for outstanding debt, convertible debentures, warrant termination payments, professional fees, expenses and other items — the purchase price is estimated to value Rosetta's shares at $.40 to $.45 each. Rosetta would become a subsidiary of Genoptix.
The boards of both companies have unanimously approved the transactions, but they remain subject to Rosetta shareholder approval at a meeting slated for April 6.
"We ... strongly urge shareholders to support this new agreement, as our cash position is insufficient to fund operations moving forward," Rosetta President and CEO Kenneth Berlin said in a statement. "Given our current market capitalization, potential for pending delisting from the Nasdaq Capital Market, and the difficult financing environment for microcap molecular diagnostics companies, we do not believe we could raise sufficient capital to continue as a going concern for an extended period of time."
During early morning trading on Wednesday, shares of Rosetta were up about 6 percent to $.35.
some Ken old news, Rosetta Genomics Plans to Sell PersonalizeDx Business
https://www.genomeweb.com/molecular-diagnostics/rosetta-genomics-plans-sell-personalizedx-business#.W4GF7ehKhPY
Anybody looking for jobs, 5 positions still open at Advaxis
https://www.advaxis.com/about-us/?pagelink=careers
Looks like Advaxis is going to borrow money to run the business.
Determine, in the first quarter of 2019, a path forward for our program related to our ongoing trial in metastatic prostate cancer with ADXS-PSA in combination with KEYTRUDA® (pembrolizumab), Merck & Co.’s, or Merck’s, anti PD-1 antibody, which early clinical data have proven worthy of continued evaluation.
Old S-3 shown 2 Merger word,4 Acquisition word. New S-3 show 7 merger word. 6 Acquisition word.
If we make one or more significant acquisitions in which the consideration includes stock or other securities, our stockholders’ holdings may be significantly diluted. In addition, stockholders’ holdings may also be diluted if we enter into arrangements with third parties permitting us to issue shares of common stock in lieu of certain cash payments upon the achievement of milestones.
We entered into a clinical development collaboration agreement with Bristol-Myers Squibb to evaluate their PD-1 immune checkpoint inhibitor, OPDIVO® (nivolumab), in combination with axalimogene filolisbac as a potential treatment option for women with metastatic cervical cancer. The ADVANCE trial was planned to evaluate this combination regimen in women with persistent, recurrent or metastatic (squamous or non-squamous cell) carcinoma of the cervix who have failed at least one prior line of systemic chemotherapy. Under the terms of the agreement, each party would bear its own internal costs and provide its immunotherapy agents. This trial has not yet been initiated as the Company is seeking a U.S. and/or European partner to fund the cervical cancer program. If a partner is not found, the study will not be initiated.
Blue, your guts and my guts were all wrong for the last two years.LOL
I guess the Chinese saying Disasters appear in double and lucks only in single. Hope disaster not happening again with KEN, let's get some lucks this time!
Look at Sellas, after Dilution, down from $9 to $0.90. what a loser!
right now we dont' know anything, we know they filed with SEC. Still many possibilities.
How many bad news CC are we going to have? could Ken break that curse!
The new S-3 added big portion of Debt Securities! Can someone explain?
What I see here is some kind of deal related to this.
The NeoAg Summit 2018,Very important Event, you don't see Advaxis there. I have very bad feeling about this company right now.
http://neo-antigen.com/about/speakers/
tks, i thought 8 million
BNY MELLON hold 8 million shares as June 30. Did they unloaded all shares in July? Can somebody find out more?
https://kyret.ky.gov/Investments/Investments%20Holdings/KTYALL%20Holdings%20as%20of%2030%20June%202018.pdf
https://kyret.ky.gov/Investments/Investments%20Holdings/KTYALL%20Holdings%20as%20of%2031%20March%202018.pdf
Still two weeks before September CC, Ken holding tight with news!
Seems like no news in August, Let's hope Ken deliver some positive news in September!
Is it possible Ken is working on a buyout deal right now?
I hope Ken is not a bull$hit guy, talk is cheap, need action to get things done!
Just one Deal could wake up this dead beast!
HOT with BMY for NSCLC? Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer
https://www.marketwatch.com/story/bristol-myers-wins-fda-approval-for-opdivo-as-treatment-for-small-cell-lung-cancer-2018-08-17
Now you know where Sean Harper is going,
An exodus of top Gilead execs continues as newly named CMO Andrew Cheng heads for the exit
https://endpts.com/an-exodus-of-top-gilead-execs-continues-as-newly-named-cmo-andrew-cheng-heads-for-the-exit/
We’re trying to ferret out where Cheng is headed. In a field bristling with new opportunities, though, that’s no easy task. I’m still working on Sean Harper.
That's what I thought, then we set for the buyout $4-5 billion!
Lets' assume KEN made deal with another BP for HOT with $400-500million dollars, what the share price will be?